As the number one provider of Nordic registry studies, Quantify sits at the heart of Scandinavia.
The Nordics typically refers to Northern European countries with similar history, culture and social structures.
They include Denmark, [β¦]
Data thatβs not fit-for-purpose can be scary, but hereβs the good news β Nordic data has many characteristics that allow it to be considered high-quality for a wide range of purposes. These [β¦]
The landscape of healthcare research is rapidly evolving, and social media is emerging as a valuable resource for real-world evidence (RWE) studies.
In one of Quantifyβs publications, ππ¨ππ’ππ₯ ππππ’π ππ’π¬πππ§π’π§π ππ¨π« ππππ₯-ππ¨π«π₯π ππ―π’πππ§ππ: π ππ¨π―ππ₯ ππ©π©π«π¨πππ‘ ππ¨ ππππ«π’π§π ππ‘π ππππ’ππ§πβπ¬ ππ¨π’ππ, [β¦]
Literature reviews are essential throughout the pharmaceutical product development lifecycle, from identifying therapeutic targets to assisting with regulatory and health technology assessment submissions and ultimately improving drug safety and patient outcomes at every stage.
This image presents the use cases for [β¦]
Nordic registers have been described as a goldmine for producing Real-World Evidence (RWE) in health and welfare research.
The benefits of national registers are well-known; these administrative registers provide comprehensive longitudinal individual-level data with complete coverage for the total population.
Today, weβd [β¦]
Quantifyβs Mathias Lilja and Johan Mesterton are co-authors on a new study on cytarabine dosing for treating secondary and high-risk AML using a synthetic control arm study design.
Since 1980βs, the standard treatment of acute myeloid leukemia (AML) is cytarabine infusion [β¦]
The Nordic region (often called Scandinavia) is home to some of the worldβs best real-world data (RWD), driving the development ofΒ pharmaceuticals and medical devices. As high-quality RWD becomes increasingly important to regulators and payers, it is critical for real-world evidence [β¦]